Effect of combination of suboptimal concentrations of P-glycoprotein blockers on the proliferation of MDR1 gene expressing cells

International Journal of Cancer

Volumn 65, Issue 3, 1996, Pages 389-397

  Hwang, Myungsil ^a   Ahn, Chang Ho ^a   Pine, P Scott ^a   Yin, Jun Jie ^a   Hrycyna, Christine A ^b   Licht, Thomas ^b   Aszalos, Adorjan ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREMOPHOR; DAUNORUBICIN; GLYCOPROTEIN P; RHODAMINE 123; VALSPODAR; VERAPAMIL;

ANIMAL CELL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG POTENTIATION; GENE EXPRESSION; LEUKEMIA CELL; LEUKEMIA L 1210; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

CALCIUM CHANNEL BLOCKERS; CELL DIVISION; CELL MEMBRANE; CYCLOSPORINS; GLYCEROL; HUMANS; LEUKEMIA; P-GLYCOPROTEIN; TRANSFECTION; TUMOR CELLS, CULTURED; VERAPAMIL;

EID: 0030067056     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960126)65:3<389::AID-IJC19>3.0.CO;2-5     Document Type: Conference Paper

References (31)

1. ASZALOS, A., PINE, P.S., PANDEY, R. and GOTTESMAN, M.M., Behavior of N-acylated daunorubicins in MDR1 gene transfected and parental cells. Biochem. Pharmacol, 50, 889-892 (1995).
2. ASZALOS, A., YANG, G.C. and GOTTESMAN, M.M., Depolymerization of microtubules increases the motional freedom of molecular probes in cellular plasma membranes. J. Cell Biol., 100, 1357-1362 (1985).
3. BOESH, D., GAVERIAUX, C., JACKEZ, B., POUTIER-MAUZANEDO, A., BOLLINGER, P. and LOOR, P., In vivo circumvention of P-glycoproteinmediated multidrug resistance of tumor cells with SDZ PSC833. Cancer Res., 51, 4226-4233 (1991).
4. BOHME, M., MULLER, M., LEIER, I., JEDLITSCHKY, G. and KLEPPLER, D., Cholestasis caused by inhibition of the adenosine triphosphate-dependent bile salt transport in rat liver. Gastroenterology, 107, 255-265 (1994).
5. BOWERS, V.D., LOKER, S., AMES, S., JENNINGS, W. and CORRY, R.J., The hemodynamic effect of Cremophor EL. Transplantation, 51, 850-857 (1991).
6. BUTTERFIELD, D.A., CHESNUT, D.A., ROSES, A.D. and APPEL, S.H., Electron spin resonance studies of erythrocytes from patients with myotonic muscular dystrophy. Proc nat. Acad. Sci, (Wash.), 71, 909-913 (1974).
7. CALLAGHAN, R., STAFFORD, A. and EPAND, R.M., Increased accumulation of drugs in a multidrug resistant cell line by alteration of membrane biophysical properties. Biochirn. biophys. Acta. 1175, 277-282 (1993).
8. CURRIER, S.J., KANE, S.E., WILLINGHAM, M.C., CARDARELLI, C.O., PASTAN, I. and GOTTESMAN, M.M., Identification of residues in the first cytoplasmic loop of P-glycoprotein involved in the function of chimeric human MDR1-MDR2 transporters. J biol Chem., 267, 25153-25159 (1992).
9. CURRIER, S.J., UEDA, K., WILLINGHAM, M.C., PASTAN, I. and GOTTESMAN, M.M., Detection and insertion mutants of the multidrug transporter. J. biol. Chem . 264, 14376-14381 (1989).
10. DAMJANOVICH, S., ASZALOS, A., MULHERN, S., SZOLLOSI, J., BALAZS, M., TRON, L. and FULWYLER, M.J., Cyclosporin depolarizes human Iymphocytes: earliest observed effect on cell metabolism. Europ. J. Immunol., 17, 763-768 (1987).
11. 3H]azidopin: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells. Brit. J Cancer. 67, 226-231 (1993).
12. FRICHE, E., JENSEN, P.B., SCHESTED, M., DEMAMD, E.J.F. and NISSEN, N.I., The solvent Cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor. Cancer Comm., 2, 297-303 (1990).
13. GOTTESMAN, M.M., SCHOENLEIN, P.V., CURRIER, S.J., BRUGGEMANN, E.P. and PASTAN, I., Biochemical basis of muitidrug resistance in cancer, In: T.G. Pretlow and T.P. Pretlow (eds.). Biochemistry of molecular aspects of selected cancers, pp. 339-371, Academic Press, San Diego, CA (1991).
14. GROF, P. and BELAOYI, J., The effect of anesthetics on protein conformation in membranes. Biochim. biophys. Acta, 734, 319-328 (1983).
15. HYDE, J.S. and SUBOZYNSKI, W., Spin labeling theory and application. In: L.J. Berliner and J. Reuben (eds.), Biological magnetic resonance, pp. 239-425, Plenum, New York (1989).
16. JAFFREZOU, J.-P., CEN, G., DURAN, G.E., MULLER, C., BORDIER, C., LAURENT, G., SIKIC, B.I. and LEVADE, T., Inhibition of lysosomal acid sphingomyelinase by agents which reverse multidrug resistance. Biochim. biophys. Acta, 1266, 1-8 (1995).
17. LAMPIDIS, T.J., KRISHAN, A., PLANAS, L. and TAPIERO, H., Reversal of intrinsic resistance to adriamycin in normal cells by verapamil. Cancer Drug Deliv., 3, 252-255 (1986).
18. MERLIN, J.L., MORJANI, H., MANFAIT, M., MARCHAL, S., RAMACCI, C., POULLAIN, M.G., PARAIRE, M. and LUCAS, C., Evaluation of combination of S9788 with verapamil, cyclosporin A or SDZ PSC833 in multi-drug resistant cells. Proc. Amer. Assoc. Cancer Res., 36, 343 (1995).
19. PASTAN, I., GOTTESMAN, M.M., UEDA, K., LOVELACE, E., RUTHERFORD, A.V. and WILLINGHAM, M.C., A retrovirus carrying MDR1 cDNA confers multiple drug resistance and polarized expression of P-glycoprotein in MDR cells. Proc. nat. Acad. Sci (Wash.), 85, 4486-4490 (1988).
20. RADERER, M. and SCHEITHAUER, W., Clinical trials of agents that reverse multidrug resistance. Cancer, 72, 3553-3563 (1993).
21. Ross, D.D., WOOTEN, P.J., TONG, Y., CORNBLATT, B., LEVY, C., SRIDHARA, R., LEE, E.J. and SCHIFFER, C.A., Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin and Cremophor EL. Blood, 83, 1337-1347 (1994).
22. SAFA, A.R., Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analog of verapamil. Proc. nat Acad. Sci. (Wash. ), 85, 7187-7191 (1988).
23. SALMON, S.A., DALTON, W.S., GROGAN, T.M., PLEZIA, P., LEHNERT, M., ROE. DJ. and MILLER, T.P., Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood, 78, 44-00 (1991).
24. SHALINSKY, D.R., JEKUNEN, A.P., ALCARAZ, J.E., CHRISTEN, R.D., KIM, S., KHATIBI, S. and HOWELL, S.B., Regulation of initial vinblastine influx by P-glycoprotein. Brit. J. Cancer, 67, 30-36 (1993).
25. SKOVSGAARD, T., Mechanism of resistance to daunorubicin in Ehrlich ascites tumor cells. Cancer Res., 38, 1785-1791 (1978).
26. SZABO, G., JR., PINE, P.S., WEAVER, J.L., RAO, P.E. and ASZALOS, A., CD4 changes conformation upon ligand binding. J. Immunol., 149, 3596-3604 (1992).
27. VAYUVEGULA, B., SLATER, L., MEADOR, J. and GUPTA, S., Correlation of altered plasma membrane potentials. Cancer Chemother. Pharmacol., 22, 163-168 (1988).
28. WEAVER, J.L., SZABO, G., JR., PINE, P.S., GOTTESMAN, M.M., GOLDENBERG, S. and ASZALOS, A., The effect of ion channel blockers, immunosuppressive agents and other drugs on the activity of the multi-drug transporter. Int. J. Cancer, 54, 456-461 (1993).
29. WEBSTER, L., LINSENMEYER, M., MILLWARD, M., MORTON, C., BISHOP, J. and WOODCOCK, D., Measurement of Cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J. nat. Cancer Inst., 85, 1685-1690 (1993).
30. WOODCOCK, D.M., JEFFERSON, S., LINSENMEYER, M.E., CROWTHER, P.J., CHOJNOWSKI, G.M., WILLIAMS, B. and BERTONCELLO, I., Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res., 50, 4199 (1990).
31. WOODCOCK, D.M., LINSENMEYER, M.E., CHOJNOWSKI, G., KRIEGLER, A.B., NINK, V., WEBSTER, L.K. and SAYER, W.H., Reversal of multidrug resistance by surfactants. Brit. J. Cancer, 66, 62-68 (1992).